| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Weng,Wei-Jun | Chairman | 0.56% | |
| Chen,Xiang-Li | Director | 0.00% | |
| Xu,Jing-Xin | Director | 29.78% | MERCURIES & ASSOCIATES HOLDING, LTD. |
| Zhou,Wen-Zhi | Director | 29.78% | MERCURIES & ASSOCIATES HOLDING, LTD. |
| Du,De-Cheng | Independent Director | 0.00% | |
| Wang,Wei-Zhong | Independent Director | 0.01% | |
| Chen,Jia-Jun | Independent Director | 0.00% |
Change Company Name to SCI Pharmtech, Inc.
2023/08/10
Change Company Name to XUFU PHARMACEUTICAL TECHNOLOGY CO., LTD. (FORMER NAME: XUFU CHEMICAL CO., LTD.)
2023/06/28
Change Company Name to XUFU PHARMACEUTICAL TECHNOLOGY CO., LTD. (FORMER NAME: XUFU CHEMICAL CO., LTD.)
2022/08/02
Change Company Name to SCI Pharmtech, Inc.
2022/08/02
Change Capital to 1,200,000,000
2021/09/15
Change Person in Charge to Weng,Wei-Jun
2014/03/12
Change Capital to 900,000,000
2013/09/25
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 360,292 | 1,523,738 | 1,204,159 |
| Operating cost | 281,132 | 1,113,073 | 853,836 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 79,160 | 410,665 | 350,323 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 79,160 | 410,665 | 350,323 |
| Operating expenses | 44,832 | 212,380 | 190,023 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 34,328 | 198,285 | 160,300 |
| Non-operating income and expenses | 5,099 | 448,572 | 203,890 |
| Net profit (loss) before tax | 39,427 | 646,857 | 364,190 |
| Income tax expense (benefits) | 7,691 | 112,179 | 69,469 |
| Net profit (loss) of ongoing business for the current period | 31,736 | 534,678 | 294,721 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 31,736 | 534,678 | 294,721 |
| Other comprehensive profit (loss), net | 28,165 | -8,333 | 202,026 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 59,901 | 526,345 | 496,747 |
| Net profit (loss) attributable to owners of parent company | 31,736 | 534,678 | 294,721 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | 59,901 | 526,345 | 496,747 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 4 | 2 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 105,581 | 860,516 | 215,767 |
| Net cash inflows (outflows) from investing activities | -267,283 | -1,009,351 | -866,203 |
| Net cash inflow (outflow) from financing activities | -33,755 | -210,840 | 1,425,665 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | -195,457 | -359,675 | 775,229 |
| Beginning balance of cash and cash equivalents | 582,382 | 942,057 | 166,828 |
| Ending balance of cash and cash equivalents | 386,925 | 582,382 | 942,057 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 1,415,451 | 1,660,387 | 1,953,239 |
| Non-current asset | 5,666,027 | 5,540,394 | 4,737,502 |
| Total asset | 7,081,478 | 7,200,781 | 6,690,741 |
| Current liability | 923,234 | 1,014,378 | 569,887 |
| Non-current liability | 621,411 | 709,471 | 1,020,901 |
| Total liability | 1,544,645 | 1,723,849 | 1,590,788 |
| share capital | 1,195,087 | 1,195,087 | 1,195,087 |
| Equity - secruity token | - | - | - |
| capital reserve | 2,234,986 | 2,234,986 | 2,233,590 |
| retained earning | 2,068,525 | 2,036,789 | 1,645,819 |
| Other equity | 38,235 | 10,070 | 25,457 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 5,536,833 | 5,476,932 | 5,099,953 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 5,536,833 | 5,476,932 | 5,099,953 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 46 | 45 | 42 |
